Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study

Table 2 NAT2 genotype frequencies and response to NTP treatment

Genotype	N	% ^b	Phenotype	NTP+ N^c	NTP+ %^d	OR (95%CI)	P value
Panel A
4/4	18	58.0	Rap	7	38.9	0.19 (0.04–0.95)	0.036
4/5B	1	3.2	Int	1	100	–	–
4/6A	6	19.4	Int	4	66.7	1.9 (0.28–11.98)	0.517
4/7B	6	19.4	Int	5	83.3	5.4 (0.55–53.27)	0.118
4/5B,6A,7B ^a	13	42.0	Int	10	76.9	5.2 (1.06–26.0)	0.036

Genotype in genders	N	%^b	Phenotype	NTP+ N^c	NTP+ %^d	OR (95%CI)	P value
Panel B
Male 4/4	9	29.0	Rap	2	22.2	0.1 (0.01–0.65)	0.012
4/5B,6A,7B^a	10	32.3	Int	8	80.0	14.0 (1.54–127.2)	0.012
Female 4/4	9	29.0	Rap	5	55.5	0.6 (0.04–0.97)	0.735
4/5B,6A,7B^a	3	9.7	Int	2	66.7	1.6 (0.10–24.7)	0.735

ISSN: 1755-8794